Unlimited Bio announced plans to inject a small cohort of healthy volunteers with two experimental gene therapies aimed at boosting muscle blood supply and growth, and ultimately pursuing longevity applications. The company says 12–15 volunteers will self‑fund travel and treatment in an unconventional early test. Unlimited Bio already markets one muscle growth therapy through clinics in Honduras and Mexico, and the program has attracted attention from influencers. Medical ethicists cautioned that multiple gene therapy injections in small, healthy cohorts will limit interpretability and raise safety and consent concerns. The trial highlights growing tensions between fast‑moving commercialized regenerative interventions and conventional clinical‑trial norms.